1. Merck discontinues nemtabrutinib after a data monitoring committee finds benefits may not outweigh risks

Merck announced on 17 November that it is discontinuing the Phase 3 BELLWAVE-011 trial of nemtabrutinib, an investigational oral non-covalent BTK inhibitor, after an external data monitoring committee review suggested that the benefits may not outweigh the risks in the study. After reviewing the data in their totality, Merck also ended the wider clinical development programme, including the Phase 3 BELLWAVE-008 and BELLWAVE-010 studies in chronic lymphocytic leukaemia and other haematologic malignancies. Investigators are being informed, patients are advised to discuss next steps with their study team, and the company has not yet disclosed which risks drove the decision; analyses are ongoing. For safety teams, a programme-wide stop triggered by one trial's benefit-risk review means coordinated communication to investigators, ethics committees and regulators across studies, and careful collection of follow-up safety data from patients moving off treatment. Merck, 17 Nov 2026

2. FDA approves adrabetadex (Lembaz) for infantile-onset Niemann-Pick disease type C with a boxed warning for permanent hearing loss

On 17 November FDA approved Lembaz (adrabetadex), an intrathecal injection given every two weeks, to reduce the risk of death in patients weighing at least 7 kg with Niemann-Pick disease type C whose neurological symptoms began before age 6; in 36 treated patients compared with a matched external control group, the risk of death was reduced by 55%. The label carries a boxed warning for hearing impairment, including permanent hearing loss, and requires a comprehensive audiology evaluation before treatment, with dose modifications based on repeated evaluations during treatment; ataxia and fatigue are also listed as warnings. For safety teams, the approval shows how a serious, known ototoxicity can be managed through baseline and serial audiology and dose adjustment, and why post-marketing monitoring will matter for a rare-disease product approved on a small treated population with an external control. FDA, 17 Nov 2026

3. Health Canada: two lots of candesartan tablets may contain esomeprazole capsules

Health Canada published on 17 November a Type II recall of two lots (PTG5442A and PTG5443A) of Taro-Candesartan 8 mg tablets, distributed nationally by Sun Pharma Canada, because the affected lots may contain esomeprazole 20 mg capsules. Patients are advised to consult their healthcare provider before stopping the product. On the same day Health Canada also published a Type III recall of four lots of PegLyte bowel-preparation powder that may contain foreign matter. For safety teams, a product mix-up in an antihypertensive means patients may miss doses without realising it, so reports of poor blood pressure control, or of unexpected capsules in candesartan packs, linked to these lots should be captured and followed up as medication errors with potential loss of efficacy. Health Canada, 17 Nov 2026

4. FDA warning letter cites an Indian sterile injectables site over contamination controls

Fierce Pharma reported on 17 November on an FDA warning letter, dated 2 November, to USV Private Limited after an April 2026 inspection of its sterile manufacturing facility in India. FDA cited the lack of written procedures to prevent microbiological contamination of sterile products, aseptic processing with "fundamental flaws in design" including unidirectional airflow deficiencies, an inadequate visual inspection programme for visible particulates and a failure to investigate atypical trends in certain injectable batches. The company had told FDA it would suspend production of certain US-bound drugs at the site, which also received an FDA warning letter in 2017. For safety and quality teams sourcing sterile products, findings like these warrant review of complaint and adverse event data for particulates, infections and injection-site reactions linked to products from the site. Fierce Pharma, 17 Nov 2026


This news brief is for information only and is not medical or regulatory advice. Source links open the original publication in a new tab.

Follow Safety Strategy on LinkedIn (opens in a new tab) for updates. All news briefs · News and articles